Imaging of Irreversible Loss of Brain Function
Bildgebende Verfahren zur Diagnostik des irreversiblen Hirnfunktionsausfalles

Authors
H. Lanfermann1, O. Schober2

Affiliations
1 Institute of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Germany
2 Department of Nuclear Medicine, University Hospital Münster, Germany

Key words
● brain death
● brain perfusion
● scintigraphy
● quality control
● CT angiography

Introduction
The fourth update of the guidelines regarding the determination of the irreversible loss of total function of the cerebrum, the cerebellum, and the brain stem came into effect on 7/6/2015 [1]. In compliance with the legal mandate according to § 16 Para. 1 Pg. 1 No. 1 of the Transplantation Act, these guidelines define the current state of medical science regarding the rules for determining death according to § 3 Para. 1 Pg. 1 No. 2 of the Transplantation Act and the rules for determining the irreversible loss of total function of the cerebrum, the cerebellum, and the brain stem including the required qualifications of physicians. They replace the guidelines from 1998 [2]. Written statements from different professional associations including the German Society of Neuroradiology (DGNR) and the German Society for Nuclear Medicine (DGN) were taken into consideration. A clear change is the replacement of the previously used term "brain death" with the more precise term "irreversible loss of brain function". An irreversible loss of brain function is usually the result of the cessation of cerebral blood circulation. If the cessation of cerebral blood circulation is detected, potentially reversible causes of clinical symptoms of loss of brain function are excluded. Therefore, the irreversibility of a loss of brain function can be determined without a wait time and follow-up clinical examinations. Methods such as Doppler/duplex ultrasound, perfusion scintigraphy, and CT angiography are used for this determination of irreversible loss of brain function.

Abstract
The updated guidelines for the determination of irreversible loss of brain function include a substantial innovation, i.e., the use of CT angiography as a supplementary technical examination. Adherence to a standardized protocol is the prerequisite for the application of CT angiography. The guidelines for standardized execution of perfusion scintigraphy are unchanged and still valid. Requirements regarding the quality of examining physicians are specified.

Key points:
▶ The guidelines for determining irreversible loss of brain function were updated.
▶ The approval of CT angiography as a supplementary examination method is a major innovation.
▶ CT angiography is to be performed to determine the cessation of cerebral blood circulation according to a standard protocol.
▶ The guidelines for the standardized implementation of perfusion scintigraphy continue to be valid.
▶ Quality requirements regarding examining physicians were specified.

Citation Format:
▶ Lanfermann H, Schober O. Imaging of Irreversible Loss of Brain Function. Fortschr Röntgenstr 2016; 188: 23–26
purpose. As in the previous guidelines, the indication for selective arterial angiography (DSA) requires the possibility of therapeutic consequences. This article is limited to the use of radiological and nuclear medicine imaging to determine the presence of irreversible loss of brain function. Special diagnostic features before and at the start of the third year of life are taken into consideration in the guidelines.

Radialogy

In addition to the description of the necessary qualifications of independent diagnosticians, the approval of CT angiography (CTA) as a supplementary examination method is a major innovation. As in the subsequently described nuclear medicine methods, use of CTA in radiology and neuroradiology requires a standardized procedure with competent evaluation.

The pathophysiological basis of the cessation of cerebral blood circulation is an increase in the intracranial pressure above the mean arterial pressure. Cerebral perfusion then ceases so that the brain has an insufficient metabolic supply. Dupas et al. [3] studied and confirmed the reliability of CT angiography for determining the cessation of cerebral blood circulation in a large study for the first time in 1998. Subsequently, CTA was approved first in France and then in Canada, Austria, and additional countries for the diagnosis of an irreversible loss of brain function ("brain death"). This study and subsequent studies [4–14] were subjected to a Cochrane analysis in 2014 [15]. The sensitivity for detecting the cessation of cerebral blood circulation in the case of a previous loss of brain function was 85%. The main cause of the lack of detection in 15% of patients was traumatic or iatrogenic opening of the cranium that prevented an increase in intracranial pressure above the mean arterial pressure. In all examinations in which the cessation of cerebral blood circulation was documented via CTA, the irreversible loss of total function of the cerebrum, the cerebellum, and the brain stem was also confirmed.

Due to the significant success of interventional stroke therapy [16, 17], CT angiography has been used nationwide in Germany in recent years to document persistent vascular occlusions. This has resulted in a qualitatively and quantitatively excellent foundation for the use of CT angiography. For the detection of the irreversible loss of brain function since 2014, an increase in intracranial pressure above the mean arterial pressure is the necessary condition for performing the examination. In all examinations in which the cessation of cerebral blood circulation was documented via CTA, the irreversible loss of total function of the cerebrum, the cerebellum, and the brain stem was also confirmed.

The following protocol is validated and to be used for adults [1].

<table>
<thead>
<tr>
<th>CTA protocol for evaluating the cessation of cerebral blood circulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>requirements</td>
</tr>
<tr>
<td>• documented clinical symptoms of loss in line with the diagnosis of irreversible loss of the total function of the cerebrum, the cerebellum, and the brain stem</td>
</tr>
<tr>
<td>• mean arterial blood pressure over 60 mm Hg</td>
</tr>
<tr>
<td>unenhanced CT</td>
</tr>
<tr>
<td>• tilting of the gantry parallel to the orbitomeatal line, CT scans from the base of the skull to the vertex with 120 kV, 170 mA; reconstructed axial scans with max. slice thickness of 5 mm</td>
</tr>
<tr>
<td>CT angiography</td>
</tr>
<tr>
<td>• intravenous administration of 65 ml of contrast agent (highly concentrated) via pressure infusion injection, followed by 30 ml of an isotonic saline solution, delivery rate of 3.5 ml/sec; the start of the spiral scan of cervical vertebral body 6, scan to the vertex is performed automatically via bolus tracking 5 seconds after at least 150 HU are achieved in the common carotid artery. 120 kV; 200 mA; table advance is: 4 cm/sec</td>
</tr>
<tr>
<td>• subsequent reconstruction of axial scans with a slice thickness of 2 mm; CT scans in units with the so-called volume scan (from cervical vertebral body 6 to vertex) are to be started automatically via bolus tracking with a time delay of 15 seconds</td>
</tr>
<tr>
<td>findings in the case of the cessation of cerebral blood circulation</td>
</tr>
<tr>
<td>• no contrast enhancement of the M1 segments of the middle cerebral artery, the A1 segments of the anterior cerebral artery, the basilar artery, the P1 segments of the posterior cerebral artery. Stasis filling can occur in V4 segments of the vertebral artery, in the PICA (posterior inferior cerebral artery) and the distal internal carotid artery (include in finding)</td>
</tr>
<tr>
<td>• good contrast enhancement of the common carotid artery and the external carotid artery and its branches</td>
</tr>
<tr>
<td>• quality control! Detection of significant contrast enhancement of the superficial temporal artery; this indicator for correct contrast administration must be carefully checked in all examinations (Fig. 1)</td>
</tr>
</tbody>
</table>

There is currently not sufficient literature regarding persons less than 18 years of age.
Nuclear medicine

The established procedure for performing perfusion scintigraphy in nuclear medicine has not changed since 1988 [2]. The revised guidelines emphasize the qualification requirements for examining physicians with respect to evaluation. In perfusion scintigraphy, static scintigraphic images record the perfusion of brain tissue via a hydrophilic tracer that is metabolically actively absorbed and bound (trapped) over many hours in a virtually unchanged concentration. The lack of absorption of the radiopharmaceutical cannot be due to medication or metabolism. Radiopharmaceuticals whose diagnostic reliability has been validated, such as Tc-99m-ethyl cysteinate dimer (ECD) and Tc-99m-hexamethylpropyleneamine oxime (HMPAO), must be used. Sufficiently substantiated studies regarding the use of biomarkers used in positron emission tomography are not currently available [19].

Different scintigraphic views must be documented. SPECT can also be performed. After bolus injection of the radiopharmaceutical, the large cranial vessels are initially visualized from a ventral direction and then static scintigraphy is performed to record tissue perfusion. Lateral projections are required to ensure the reliability of perfusion examinations in the vertebrobasilar region. If there is still doubt due to overlapping of soft tissue structures, superimposition-free visualization with SPECT is necessary.

The scintigraphic criteria of an irreversible loss of brain function are a lack of visualization of cerebral vessels and cerebral perfusion and enhancement of the radiopharmaceutical in the brain tissue [4, 20 – 26].

Quality control should be performed in vitro by determining the labeling yield (ideally greater than 90 %) via thin layer chromatography. In addition, the physiological distribution of the radiopharmaceutical should be checked by scintigraphy of the thorax and abdomen as an in vivo quality control.

Perfusion scintigraphy must be monitored and evaluated by a nuclear medicine specialist.

References

1. Beschluss der Bundesärztekammer über die Richtlinie gemäß § 16 Abs. 1 S. 1 Nr. 1 TPG für die Regeln zur Feststellung des Todes nach § 3 Abs. 1 S. 1 Nr. 2 TPG und die Verfahrensregeln zur Feststellung des endgültigen, nicht behebbaren Ausfalls der Gesamtfunction des Großhirns, des Kleinhirns und des Hirnstamms nach § 3 Abs. 2 Nr. 2 TPG, Vierte Fortschreibung. Dtsch Arztebl 2015; 112: A-1256/B-1052/C-1024


19 Bender A, Jox RJ, Grill E et al. Persistent vegetative state and minimal conscious state. Dtsch Arztebl Int 2015; 112: 235–242